|Articles|October 17, 2011
Michigan Institute for Clinical & Health Research Selects OpenClinica Clinical Trial Software
Advertisement
The Michigan Institute for Clinical & Health Research (MICHR) at the University of Michigan has selected the OpenClinica Enterprise clinical trial software platform to support a growing clinical study portfolio. Starting this fall, MICHR will begin deployment of OpenClinica for a wide variety of clinical trials.
According to Jim Maszatics, Clinical Research Informatics Core (CRIC) Manager at MICHR, OpenClinica offers a robust infrastructure that will enhance MICHR’s competitiveness for extramural funding. “Static budgets and budget cuts from the NIH are causing government-sponsored grants to become more competitive than ever. With OpenClinica, we are able to put in place an enterprise-quality, regulatory compliant electronic data capture and clinical data management system that will make us more attractive to both government-sponsored and industry-sponsored clinical trials.”
In addition to its regulatory compliance capabilities, MICHR cited OpenClinica’s flexibility to support a wide variety of studies off the same platform, thereby increasing the institute’s efficiency. This efficiency will serve MICHR well in its support of a large and growing number of diverse clinical studies.
According to Jim Maszatics, Clinical Research Informatics Core (CRIC) Manager at MICHR, OpenClinica offers a robust infrastructure that will enhance MICHR’s competitiveness for extramural funding. “Static budgets and budget cuts from the NIH are causing government-sponsored grants to become more competitive than ever. With OpenClinica, we are able to put in place an enterprise-quality, regulatory compliant electronic data capture and clinical data management system that will make us more attractive to both government-sponsored and industry-sponsored clinical trials.”
In addition to its regulatory compliance capabilities, MICHR cited OpenClinica’s flexibility to support a wide variety of studies off the same platform, thereby increasing the institute’s efficiency. This efficiency will serve MICHR well in its support of a large and growing number of diverse clinical studies.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- Q&A: Strategies for Successful Global Clinical Trial Delivery
September 12th 2025
- Vabysmo Shows Long-Term Efficacy and Safety in Wet AMD, PCV Patients
September 12th 2025
- Latest NIMBLE Study Results Highlight Progress in gMG Research
September 12th 2025
- ACT Brief Episode 8: Expert Insights on the Future of Obesity Drug Trials
September 11th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
FDA Fast Tracks Sanofi’s Intravitreal Gene Therapy for Neovascular Age-Related Macular Degeneration
2
Vabysmo Shows Long-Term Efficacy and Safety in Wet AMD, PCV Patients
3
Q&A: Strategies for Successful Global Clinical Trial Delivery
4
Trial Data Leads to NCCN Recommendation for Modeyso in Recurrent High Grade Glioma Patients
5